RxDoctor Payments Data

Andrew Velazquez, MD

Ophthalmology · Mountain Brk, ALNPI 1013930825

Payments from drug & device makers

$2,991in general payments, 2019–2025

Across 89 payments — averaging $33.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Johnson & Johnson Surgical Vision, Inc.$561
  • NEW World Medical,inc.$329
  • Glaukos Corporation$186
  • Sun Pharmaceutical Industries Inc.$137
  • AbbVie$107
  • plus $609 from 15 others

What the payments were for

  • Food & beverage$2,991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,991 in reported general payments places this provider in the 65th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$260,157
Medicare patients
732
Services billed
1,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate69$27,027
Prednisolone Acetate569$24,030
LumiganBimatoprost54$20,605
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol86$13,286
XiidraLifitegrast11$11,628
Ketorolac Tromethamine389$11,580
RocklatanNetarsudil Mesylat/Latanoprost29$9,821
CombiganBrimonidine Tartrate/Timolol23$7,054
SimbrinzaBrinzolamide/Brimonidine Tart31$6,493
Cyclosporine20$6,432
Latanoprost450$6,285
Travoprost27$5,639
MoxifloxacinMoxifloxacin Hcl171$5,206
Brimonidine Tartrate38$4,225
Fluorometholone45$3,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$97$36,84898 claims
AbbVieLumigan, Combigan$107$27,66077 claims
Bausch & Lomb Americas Inc.Xiidra$40$11,62811 claims
AlconSimbrinza$1,063$6,49331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Mountain Brk

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →